• Sales of $3.3 million reflect seasonal reduction in respiratory testing
• Revenue contribution from Australia, EMEA and US, with international markets growing
• Initial US sites serving as reference sites to support customer acquisition

Genetic Signatures Ltd reported sales of $3.3 million (unaudited) for Q2 FY26, reflecting a seasonal reduction in respiratory testing rates in Australia. Revenue for the quarter originated from all three regions - Australia, EMEA and the US - with international markets contributing a growing share of group revenue. The company's initial US sites are now serving as reference sites to demonstrate the clinical value of its diagnostic solution and support the acquisition of additional customers. In the UK, revenue was underpinned by improving gastroenteric sales performance, reflecting growing momentum with National Health Service (NHS) clientele. The company also made continued progress on the development of an automated, high-throughput solution and maintained a strong balance sheet with $29.7 million in cash and term deposits as of 31 December 2025. During the quarter, the company advised that CEO Allison Rossiter will be leaving the company in late February 2026 to take on a role with a global pharmaceutical company. The board has initiated a search for a new CEO and is implementing interim arrangements to maintain continuity of leadership and operations.

The company remains focused on strengthening its presence in Australia while accelerating global expansion. With the initiatives and team in place, the company remains confident in its ability to continue diversifying revenue by growing international markets beyond its current primarily domestic business.